Theravance Biopharma EBIT

The latest EBIT for TBPH is $-64K as of June 2026. That compares with $40M in the prior-year period — down 100.2% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Theravance Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, TBPH's EBIT moved from $40M to $-64K — a 100.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Theravance Biopharma's operating scale or balance-sheet position.

Against Healthcare companies, TBPH currently prints $-64K for EBIT, while the sector average sits near $23B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Theravance Biopharma's growth, margins, and balance sheet.

A EBIT figure of $-64K for TBPH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting TBPH's EBIT ($-64K), review year-over-year change from $40M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.